Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10233892rdf:typepubmed:Citationlld:pubmed
pubmed-article:10233892lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:10233892lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:10233892lifeskim:mentionsumls-concept:C0162595lld:lifeskim
pubmed-article:10233892lifeskim:mentionsumls-concept:C1442792lld:lifeskim
pubmed-article:10233892lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:10233892lifeskim:mentionsumls-concept:C0023775lld:lifeskim
pubmed-article:10233892pubmed:issue10lld:pubmed
pubmed-article:10233892pubmed:dateCreated1999-6-10lld:pubmed
pubmed-article:10233892pubmed:abstractTextWe measured the urinary excretion of Isoprostane F2alpha-III and Isoprostane-F2alpha-VI, two markers of in vivo lipid peroxidation, and the circulating levels of the prothrombin fragment F1+2, a marker of thrombin generation, in 18 antiphospholipid antibodies-positive patients, in 18 antiphospholipid antibodies-negative patients with systemic lupus erythematosus, and in 20 healthy subjects. Furthermore, 12 patients positive for antiphospholipid antibodies were treated with (n = 7) or without (n = 5) antioxidant vitamins (vitamin E at 900 IU/d and vitamin C at 2, 000 mg/d) for 4 weeks. Compared with antiphospholipid antibodies-negative patients, antiphospholipid antibodies-positive patients had higher urinary values of Isoprostane-F2alpha-III (P =. 0001), Isoprostane-F2alpha-VI (P =.006), and plasma levels of the prothrombin fragment F1+2 (P =.0001). In antiphospholipid-positive patients, F1+2 significantly correlated with Isoprostane-F2alpha-III (Rho =.56, P =.017) and Isoprostane-F2alpha-VI (Rho =.61, P =.008). After 4 weeks of supplementation with antioxidant vitamins, we found a significant decrease in F1+2 levels (P <.005) concomitantly with a significant reduction of both Isoprostane-F2alpha-III (P =.007) and Isoprostane-F2alpha-VI (P <.005). No change of these variables was observed in patients not receiving antioxidant treatment. This study suggests that lipid peroxidation might contribute to the activation of clotting system in patients positive for antiphospholipid antibodies.lld:pubmed
pubmed-article:10233892pubmed:languageenglld:pubmed
pubmed-article:10233892pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10233892pubmed:statusMEDLINElld:pubmed
pubmed-article:10233892pubmed:monthMaylld:pubmed
pubmed-article:10233892pubmed:issn0006-4971lld:pubmed
pubmed-article:10233892pubmed:authorpubmed-author:ContiFFlld:pubmed
pubmed-article:10233892pubmed:authorpubmed-author:VioliFFlld:pubmed
pubmed-article:10233892pubmed:authorpubmed-author:FitzGeraldG...lld:pubmed
pubmed-article:10233892pubmed:authorpubmed-author:ValesiniGGlld:pubmed
pubmed-article:10233892pubmed:authorpubmed-author:RokachJJlld:pubmed
pubmed-article:10233892pubmed:authorpubmed-author:IulianoLLlld:pubmed
pubmed-article:10233892pubmed:authorpubmed-author:PraticòDDlld:pubmed
pubmed-article:10233892pubmed:authorpubmed-author:FerroDDlld:pubmed
pubmed-article:10233892pubmed:issnTypePrintlld:pubmed
pubmed-article:10233892pubmed:day15lld:pubmed
pubmed-article:10233892pubmed:volume93lld:pubmed
pubmed-article:10233892pubmed:ownerNLMlld:pubmed
pubmed-article:10233892pubmed:authorsCompleteYlld:pubmed
pubmed-article:10233892pubmed:pagination3401-7lld:pubmed
pubmed-article:10233892pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:meshHeadingpubmed-meshheading:10233892...lld:pubmed
pubmed-article:10233892pubmed:year1999lld:pubmed
pubmed-article:10233892pubmed:articleTitleOngoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation.lld:pubmed
pubmed-article:10233892pubmed:affiliationInstitute of Clinical Medicine I, University "La Sapienza," Rome, Italy.lld:pubmed
pubmed-article:10233892pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10233892pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10233892pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10233892lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10233892lld:pubmed